Franklin Resources Inc. Sells 277,033 Shares of Medtronic PLC $MDT

Key Points

• Franklin Resources Inc. trimmed its Medtronic stake by 2.4% in Q3, selling 277,033 shares and now holding 11,492,577 shares (~0.90% of the company) valued at about $1.094 billion.
• Medtronic agreed to acquire Scientia Vascular for $550 million, a strategic tuck‑in to bolster its neurovascular access and therapeutic portfolio and enhance "time‑is‑brain" capabilities.
• Medtronic beat quarterly estimates with $1.36 EPS (vs. $1.34) and $9.02B revenue (vs. $8.89B), set FY26 guidance of 5.620–5.660 EPS, and declared a $0.71 quarterly dividend (3.2% yield).

Franklin Resources Inc. reduced its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 2.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,492,577 shares of the medical technology company's stock after selling 277,033 shares during the quarter. Franklin Resources Inc. owned about 0.90% of Medtronic worth $1,094,553,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in MDT. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the 2nd quarter valued at approximately $27,000. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new stake in shares of Medtronic in the third quarter valued at approximately $29,000. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medtronic in the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in shares of Medtronic in the third quarter worth $34,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire Scientia Vascular for $550 million to bolster its neurovascular access and therapeutic portfolio — a strategic tuck‑in that expands “time‑is‑brain” capabilities and complements existing neurovascular product lines. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Neutral Sentiment: Analyst coverage is active — a Benzinga deep dive summarizes 10 analyst ratings showing mixed views on MDT’s valuation and growth prospects; this keeps price target dispersion and investor debate elevated. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Neutral Sentiment: Management commentary at the Barclays Healthcare Conference (transcript) reaffirmed strategy and longer‑term objectives; investors will be parsing any incremental detail on margin drivers, product cadence and the FY26 guide. Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Leadership change: Sean Haag named president of Medtronic’s ENT business — an operational move that matters for execution in ENT but is not expected to materially alter near‑term financials. Medtronic names Sean Haag president of ENT business
• Negative Sentiment: Competitive pressure from NeuroPace (NPCE) — recent coverage highlights product and reimbursement tailwinds for NeuroPace’s RNS system that could accelerate adoption in neuromodulation and pose longer‑term share/price pressure in adjacent markets. Investors view stronger competitor momentum as a headwind for Medtronic’s neuromodulation ambitions. NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
• Negative Sentiment: Macro/market volatility (rising VIX) is weighing on large‑cap medical device names, increasing downside risk from sector‑wide flows and multiple compression rather than company‑specific fundamentals. When Fear Spikes, These 5 Quiet, Overlooked Stocks Keep Delivering

Medtronic Trading Down 1.7%

Shares of MDT stock opened at $89.79 on Wednesday. The firm has a fifty day moving average of $98.45 and a 200-day moving average of $97.00. The stock has a market cap of $115.28 billion, a price-to-earnings ratio of 25.01, a P/E/G ratio of 2.29 and a beta of 0.71. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT - Get Free Report) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm's revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic's payout ratio is presently 79.11%.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of research reports. Leerink Partners reissued an "outperform" rating and issued a $119.00 price target on shares of Medtronic in a report on Tuesday. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the company a "neutral" rating in a research note on Wednesday, November 19th. Robert W. Baird decreased their target price on Medtronic from $103.00 to $100.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 18th. William Blair upgraded Medtronic from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 6th. Finally, Wall Street Zen cut Medtronic from a "buy" rating to a "hold" rating in a report on Sunday, March 1st. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $110.74.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the company's stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.26% of the company's stock.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.